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Summary: In orderte optimize the identification of clinically relevant quantities of Bordetella pertussis in nasopha-
ryngeal swabs, an automated assay introducing competitive polymerase chain reaction was established. A 183 base
pair DNA fragment from a repetitive region of the Bordetella pertussis genome was amplified in a polymerase
chain reaction. An internal control DNA with nine base substitutions was coamplified in the same reaction. The
differentiation between the amplified B. pertussis DNA and the internal control was based on hybridisation against
two different probes using Enzymun Test® DNA Detection (Boehringer Mannheim). Nasopharyngeal swabs from
serologically positive patients, clinically diagnosed with whooping cough, serologically negative patients after
contact with B. pertussis and a negative group were compared. The advantages of competitive PCR are a reduced
risk of false-positive and false-negative results and the possibility to differentiate between the different PCR posi-
tive groups.
Introduction
The importance of the polymerase chain reaction for the
identification of the Gra/w-negative bacterium Borde-
tella pertussis in nasopharyngeal swabs or aspirates used
for early diagnosis of whooping cough or epidemiologi-
cal studies has increased in recent years. Standard meth-
ods like culture of B. pertussis or ELISA serology are
not sensitive enough or not useful for an early and fast
identification of the infectious agent (1—5). For the
diagnosis of whooping cough, various parts of the B.
pertussis genome have been used for amplification in
PCR. Assays were described by different authors detect-
ing a part of the pertussis toxin gene (4—7), the adenyl-
ate cyclase gene (8) or a repetitive region of the B. per-
tussis genome (2—4, 9—11). All regions are shown to
be suitable for identification of B. pertussis with dif-
ferent cross reactivities in detecting other Bordetellae
like A parapertussis, B. bronchiseptica orB. avium. Our
assay involves the amplification of the described repeti-
tive element of the B. pertussis genome, because detec-
tion of this region results in an increased sensitivity
(2,4).
Frequently described problems in the routine use of the
polymerase chain reaction include false-positive results
due to contaminations, especially by carry over of DNA
from other samples or positive controls. Secondly, false-
negative results are obtained due to any disturbances in
the entire assay, which involves all parts from DNA iso-
lation to detection of the amplified DNA (11), such as
inhibitory effects during PCR amplification. Another
problem is the clinical relevance of any positive result
in an assay with such a high sensitivity like a nested
polymerase chain reaction. In order to investigate the
questions we established a competitive polymerase
chain reaction (12, 13) using a modified part of the re-
petitive element of B. pertussis as internal control. We
evaluated our assay by analyzing nasopharyngeal swabs
from serologically confirmed children with whooping
cough and serologically negative children with proven
contact with B. pertussis.
Materials and Methods
Samples
Samples were collected from patients from a pacdiatric practice
and from the children's hospital of the Hannover Medical School
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between March 1992 and June 1994. Nasopharyngeal swabs were
collected with fine tip dacron swab sets (Transwab MD 173). The
samples were placed in 100 μΐ physiological saline solution in a
sterile reaction tube (Eppendorf, 0.5 ml), resuspended and stored
at -20 °C until needed.
DNA i so la t ion
An easy one tube DNA isolation method was performed as pre-
viously described by Lichtinghagen et al. (11). A second method
for DNA isolation involved proteinase-K treatment and subsequent
adsorption of the DNA to a DNA-binding matrix. For this purpose
we used QIAamp Blood Kit (Qiagen) according to the manufactur-
er's instructions.
A third method was to incubate samples for 10 min at 99 °C, ex-
tract the solution with an equal volume of phenol/chloroform
(1 + 1) mixture and precipitate with a threefold volume ethanol.
The sedimented DNA was washed with 500 μΐ ethanol (75 g/l),
dried and dissolved in 100 μΐ Η2Ο.
Implementa t ion of the polymerase chain reaction
PCR was performed as described by Saiki et al. with some modifi-
cations (14). For a more specific annealing reaction, tetramethyl-
ammonium chloride was used in the reaction mix (15). And we
also preferred a hot start PCR in order to obtain a higher yield.
Samples (30 μΐ) treated as described above were placed in a 0.5
ml Eppendorf tube, overlaid with 50 μΐ of paraffin and incubated
at 95 °C for 10 minutes (hot start PCR). PCR-mix (20 μΐ) and 2
units of Taq polymerase1) were then added at 80 °C (PCR-mix: see
below). The PCR was carried out with the primer pair Perl/Per3-
rev in a thermocycler (Landgraf) for 35 cycles. The cycles con-
sisted of a denaturation step at 94 °C for 60 seconds, annealing at
59 °C for 60 seconds and elongation at 72 °C for 60 seconds.
The oligonucleotide sequences were:
PERI: 5'-GAT TCA ATA GOT TGT ATG CAT GGT T-31,
PER3-rev: 5'-GCT TCA GGC ACA CAA ACT TGA TGG-31,
PCR-mix (50 μΐ total volume): 0.2 mmol/1 dNTPs (Fa. Pharmacia,
Boehringer Mannheim), 1 μπιοΐ/ΐ each of the oligonucleotides
(Perl, Per3rev) HPLC grade (Biometra), 5 μΐ PCR buffer (Boeh-
ringer Mannheim), 0.05 mmol/1 tetramethylammonium chloride,
2U Taq polymerase (Cetus, Boehringer Mannheim) ad 20 μΐ Η2Ο.
For an immunochemical detection, the DNA was labelled with di-
goxigenin-ll-2'-desoxy-uridine-5l-triphosphate, which was added
to the desoxynucleoside-triphosphate mixture in a ratio 8 : 1
(dTTP/Dig-11-dUTP). In case of a competitive polymerase chain
reaction normally 1 pg internal control DNA was added to the
PCR-mix.
Avoiding contaminat ion in the PCR
In order to avoid false positive results from contaminated PCR
samples, only sterile pipette tips with filters (Multy Technology
Inc.) were used. The risk of contaminations was further reduced
by using apportioned stock mixes to dimmish the number of pipet-
') Enzymes:
T&ypolymerase:
EcoRl:
Hindlll:
BamHl:
Ί4 DNA ligase:
DNA polymerase EC 2.7.7.7 from Thermits
aquaticus
restriction endonuclease from E. coli
restriction endonuclease from Haemophilus
in uenzae Rd
restriction endonuclease from Bacillus amy-
loliquefaciens H
DNA ligase from T4-infected E. coli
ting steps. The competitive polymerase chain reaction made it pos-
sible to avoid a separate positive control, which would have been
an additional source of contaminations. Working areas for sample
preparation, PCR and detection of DNA were strictly separated.
Immunochemical detection of DN^r fragments
Enzymun Test® DNA detection with an ES 300 analyser
PCR-specifically amplified and digoxigenin labelled sample were
added to 360 μΐ denaturing reagent (50 mmol/1 NaOH) and pipetted
into the ES 300 analyser. The reaction program was started accord-
ing to the Enzymun Test® DNA Detection instructions (Boehringer
Mannheim). The following reagents were also necessary: Biotiny-
lated capture probes were added to different hybridisation solutions
(phosphate buffer, pH 6.5) to a final concentration of 90 μg/l.
Capture probe (B. pertussis assay):
5' Biotin-CTG GAC CAT TTC GAG TCG AC 31
Capture probe (internal control):
5' Biotin-CTG CAC GTA GGA TCC TCG AC 3'
B. pertussis specific DNA and the internal control DNA were de-
tected by binding of the biotin labelled nucleic acids to the strept-
avidin solid phase (Enzymun Test® Streptavidin Tubes, Boehringer
Mannheim) in two different reactions. A peroxidase conjugated
anti-digoxigenin antibody was added to label the digoxigenin. The
complex was then visualized by addition of the chromogen dir
ammonium 2,2'-azmo-bis(3-ethylbenzothiazoline-6-sulphonate)
(ABTS) giving rise to a green colour, the intensity of which y/as
measured at 422 nm. Positive samples were determined by a cuT
off value (cut-off = 2 X Eneg). Samples which had absorbances
between —25% and + 50% of the cut-off value were seen as bor-
derline values and were repeated.
Site directed mutagenesis using polymerase chain
reaction (16)
The whole target DNA region was amplified in two different poly-
merase chain reactions under standard conditions (14) with the
primer pairs R1/R3 and R2/R4. The oligonucleotides Rl and R2
were the flanking primers of the target region with additional re-
cognition sites for EcoRl1) (Rl) and Hindlll1) (R2). The oligonu-
cleotide R3 corresponded to an internal part of this DNA region
adjacent to the DNA sequence of oligonucleotide R4. Restriction
endonuclease BamHl1) recognition sites at the 5'-end of the primers
R3 and R4 for joining these fragments sites and three additional
base substitutions in the sequence of oligonucleotide R4 were in-
troduced.
The sequences were:
Rl: TAA GAA TTC GAT TCA ATA GGT TGT ATG CAT GGT
R2: TAA AAG CTT CTC CAC GAT AGC CAG CGC CT
R3: TAA GGA TCC TCG ACG TAG GAA GGT CAA TCG
R4: TAA GGA TCC TAC GTC CAG CAA TTG ATC GCC
The amplified products were gel purified using Sephaglas-Kit
(Pharmacia) and cleaved with EccRl and BamHl (R1/R3) and with
Hindlll and BamHl (R2/R4) to obtain DNA ready for ligation.
The enzymes were inactivated by phenol/chloroform extraction and
ethanol precipitation. DNA fragments were subsequently dissolved
in 10 μΐ Tris/EDTA buffer (10 mmol/1 Tris-HCl, pH 7.9, 1 mmol/1
EDTA) and ligated with EcoKUHindllV) digested vector
pUCBM20 (Boehringer Mannheim) using T4-DNA4igase!) (Boeh-
ringer Mannheim). Competent bacterial strain £. coli C600 was
transformed with the recombinant plasmid DNA (17).
Plasmid preparation
LB medium (500 ml) containing 100 mg/l ampicillin was inocu-
lated with 5 ml of a late log culture of a positive bacterial clone.
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The culture was incubated under vigorous shaking (180 min""1) at
37 °C for 6 hours (17). Plasmid preparation was performed accord-
ing to instructions of Qiagen Plasmid Maxi Kit (Qiagen). The DNA
was further extracted with phenol/chloroform and ethanol precipi-
tated after RNase treatment of the plasmid DNA. The preparation
was checked on an agarose gel. Agarose gel electrophoresis was
performed on 20 g/1 agarose gels in Tris-borate buffer containing
89 mmol/1 Tris-borate, 2 mmol/1 EDTA, 400 μg/l ethidium bro-
mide, pH 8.0 (17). Electrophoresis was carried out for 45 minutes
with 10 V/cm in Tris-borate buffer. The DNA bands were detected
with an UV Iransilluminator at 312 nm (17). The concentration of
the DNA was determined by measuring the absorbance at 260 nm.
An absorbance of 1.0 corresponds to approximately 50 mg/1
double-stranded DNA (17).
Results
Cloning the internal control DNA in E. coli
B. pertussis DNA isolated from a positive nasopharyn-
geal swab was amplified in two separate polymerase
chain reactions using the primer pairs R1/R3 and R2/R4
(see fig. 1). All primers contained additional recognition
sites for restriction endonucleases (see Material and
Methods). The joining of the two resulting DNA frag-
ments via the BamHl restriction site of R2 and R4 gen-
erated six substitutions in the original sequence. More
bases were exchanged by introducing three mismatches
next to the cloning site of oligonucleotide R4. After liga-
tion with pUC BM20 and amplification in E. coli the
recombinant plasmid was purified (see Material and
Methods) and used as internal control DNA which was
added to the PCR-mix.
Checking the assay conditions with internal
control DNA
First the internal control DNA was tested for cross reac-
tivity after hybridisation with the pertussis capture probe
under the described assay conditions (see Material and
Methods). For this purpose dilutions of the internal con-
trol DNA were prepared from 10~8 g to 10~13g per as-
say and amplified in polymerase chain reactions with the
primer pair Perl/Per3 rev. Internal control and pertussis
capture probe were hybridised with the amplified pro-
ducts in two different reactions. Table 1 shows absor-
bances at 422 nm for these two detection steps from
dilutions of the internal control DNA. Under standard
assay conditions there was no cross reactivity between
CTAGCTGTGA AGATTCAATA GGTTGTATGC ATGGTTCATC CGAACCGGAT TTGAGAAACT GGAAATCGCC AACCCCCCAG
> ΡθΠ
EcoRJ > R1
TTCACTCAAG GAGCCCGGCC GGATGAACAC CCATAAGCAT GCCCGATTGA CCTTCCTACG TCGACTCGAA ATGGTCCAGC
Probe < Biotin
R3 <
AATTGATCGC CCATCAAGTT TGTGTGCCTG AAGCGGCCCG. . .
Per3-rev <
GGCCAAGGCG CTGGCTATCG TGGAGCTCCG
R2 < HindTIJ
. .CCTTCCTACG TCGACTCGAA ATGGTCCAGC. . . B. pertussis
****** ***
. . CCTTCCTACG TCGAGGATCC TACGTCCAGC. . . Internal control
Fig. 1 Construction of the internal control DNA
(a) The PCR amplified section from a repetitive element of B.
pertussis for detection of the infectious agent in nasopharyngeal
aspirates or swabs is shown (2, 11). Oligonucleotide sequences
used for amplification (see Materials and Methods) are labeled
with arrows, additional restriction sites are shown in italics. The
resulting DNA fragments have sizes of 183 base pairs (Perl/
PerSrev), 380 base pairs (R1/R2), 145 base pairs (R1/R3) and
241 base pairs (R2/R4).
M
200 —
100 —-
3 4
(b) The resulting nine sequence alterations in the internal control
DNA after ligating the R1/R3 and R2/R4 DNA fragments with
pUCBM20 are marked with asterisks in the sequence of the capture
probe binding region.
(c) Electrophoretic separation of B. pertussis DNA (lane 1) and
internal control DNA (lane 2) after PCR with primer pair Perl/
Per3rev results in 183 base pairs DNA fragments. After digestion
with restriction endonuclease BamHl (lane 3: B. pertussis DNA,
lane 4: internal control DNA) bands of 138 and 45 base pairs were
only detected in lane 4.
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Tab. 1 Test for cross reactivity of the internal control DNA with
the pertussis capture probe.
The cloned internal control DNA was diluted in several steps (10
- 10~ l 3g per assay) and amplified in a PCR using the primer
pair Perl/Per3rev (see Materials and Methods). Two capture probes
(pertussis, internal control) were used for hybridisation. Absor-
bances at 422 nm after detection of the PCR products with the
ES300 analyser (Enzymun Test® DNA Detection) are shown.
Quantity [g] 1<T8 1(T9 ΙΟ"'0 ΚΓ" 1(T'2 1(T13
Pertussis 0.044 0.041 0.041 0.039 0.043 0.034
capture probe
Internal control 6.66 6.72 6.69 6.50 6.50 5.89
capture probe
internal control DNA and pertussis capture probe. Thus
the introduced mismatches in the capture probe binding
site are shown to be suitable for a differentiation of B.
pertussis and internal control in the assay.
The use of competitive PCR may result in a decreased
amplification rate of the required DNA fragment. There-
fore it was necessary to determine a minimum quantity
of internal control DNA which could be coamplified in
polymerase chain reaction. Table 2 shows the results of
these investigations. Internal control DNA was diluted
from 10~8g to 10~15g per assay. From each dilution
four amplifications were performed and the products
were detected with internal control capture probe using
Enzymun Test® DNA Detection. Internal control DNA
(1 pg per 50 μΐ total volume in the reaction mixture) was
the lowest concentration which led to constant absor-
bances at 422 nm. This fact is indicated by the increas-
ing coefficients of variation at lower quantities of in-
ternal control DNA. Furthermore we tested the competi-
tive PCR with dilutions from 10~8 g to 10~14 g per as-
say of the repetitive DNA fragment of B. pertussis
cloned into pBluescript SK+ (11) and a constant amount
of 1 pg internal control DNA per reaction (see fig. 2).
As expected we found a suppression of internal control
DNA amplification at higher B. pertussis DNA concen-
trations and vice versa. In ten different runs we investi-
gated mean values for negative controls. We found for
internal control capture probe A422nm =s 5·83, SD = 0.6
(n = 20) and for pertussis capture probe A422nm
= 0.046, SD = 0.02 (n = 20). The cut-off value for
negative samples was set at A^nm (pertussis capture
probe) < 0.1 which is due to Enzymun Test® DNA De-
tection specifications (negative sample < 2 X A422nm)·
Competitive polymerase chain reaction with
patient samples
For reliable identification of Bordetella pertussis in na-
sopharyngeal swabs it was necessary to check the qual-
ity of the described assay conditions. Therefore we
tested different pools of stored patient samples. The first
group includes patients without any signs of infection
which tested negative in a polymerase chain reaction
(11). The absorbances after detection of the amplified
DNA using pertussis capture probe were in the same
range compared to the negative controls (A422nm
= 0.03, SD = 0.002 (n = 10)). Measuring negative pa-
tient samples it was possible to study inhibitory effects
of the DNA preparation techniques used in the assay.
We tested a commercial DNA preparation kit and two
usual methods for DNA preparation (see materials afrd
methods). The dependence of the quality of DNA prepa-
ration methods on internal control DNA amplification is
shown in table 3. Coamplification of 1 pg internal con-
trol DNA in a competitive PCR with reproducible high
absorbances in the detection step was only possible
using phenol/chloroform purified DNA from nasopha-
ryngeal swabs. In cases in which other DNA preparation
methods were used it became necessary to increase the
amount of internal control DNA.
Finally we compared serologically confirmed patients
with whooping cough and PCR-positive, serologically
negative patients with proven contact to B. pertussis.
With these test results we wanted to show a possible
detection of different amounts of the infectious agents
in nasopharyngeal swabs between the point of infection
and the paroxysmal stage. Results of these comparisons
are shown in figure 3. Positive tests were confirmed in
both groups using a competitive PCR assay. In addition,
a ratio of absorbances at 422 nm of the B. pertussis
Tab. 2 Determining the minimum quantity of internal control
DNA in the assay.
amplifications were performed. Hybridisation occured only with
the internal control capture probe. Mean values, standard devia-
Intemal control DNA was diluted in several steps (1(T8 - I(r15g tions and coefficients of variation are shown for the measured ab-
per assay) and PCR amplified using the primer pair Perl/Per3rev sorbances at 422 nm.
(see Materials and Methods). From each dilution four
Quantity [g]
Mean value
Standard deviation
Coefficient of variation [%]
10~8
6.70
0.04
1
10~9
6.53
0.07
1
10-io
6.67
0.13
2
ΙΟ'11
6.53
0.11
2
io-12
6.34
0.2
3
10~13
1.65
1.87
113 '
10-i4
0.07
0.05
71
io-15
0.82
1.57
191
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ΙΟ'14 ΙΟ'12 ΙΟ"10 ΙΟ'8 '
Positive control DNA [g]
Fig. 2 Competitive polymerase chain reaction of positive con-
trol DNA
The B. pertussis DNA fragment (183 base pairs; Perl/Per3rev)
cloned in pBluescript KS+ (11) was diluted from 10~8g to
10~15g per assay and coamplified with 10~ l 2g internal control
DNA. The primers Perl and Per3rev were used in the PCR. Result-
ing DNA fragments were detected after hybridisation with pertussis
(a) and internal control capture probe (b) using Enzymun Test®
DNA Detection (see Materials and Methods). Absorbances at 422
nm were plotted against concentrations of positive control plas-
mid DNA.
DNA and the internal control DNA led to a better sepa-
ration of different collectives. In case of the serologi-
cally negative group we found maximum values only
around 1.5 (values for negative samples were about
0.01). In the serologically positive group values between
10 and 100 could be obtained. Such a differentiation was
not possible in a comparison only of the absorbances of
the amplified B. pertussis DNA. To determine the influ-
ence of the concentration of internal control DNA on
the sensitivity of the assay, we investigated pooled sam-
ples from serologically positive and negative patients
with high absorbances in the detection assay (> 6.0),
and samples with low absorbances (< 0.3).
From these pools four competitive PCR assays were
performed with increasing concentrations (10~12
— 10~9g per assay) of the internal control DNA. In
Tab. 3 Effect of DNA preparation technique on internal control
DNA amplification.
Samples from patients without any signs of wooping cough were
amplified in a competitive PCR with 1 pg internal control DNA
after different routes of DNA isolation. Mean values for absor-
bances at 422 nm after hybridisation with internal control capture
probe, standard deviations and coefficients of variation are listed.
DNA preparation method ^internal control $D
Proteinase-K treatment 35 0.054 0.003 6
and boiling of the sample
QIAamp Blood Kit 25 0.71 0.91 128
Phenol/chloroform 10 4.47 0.37 8
case of the positive group a competition with about
10~~9g internal control DNA and in case of the nega-
tive group with about 10~n to 10~~1 2g leads to a
ratio of 1 which indicates an equimolar amount of B.
pertussis and internal control DNA fragment. This
shows that using an amount of 10~ l 2g of internal
control plasmid DNA does not lead to a decreased
diagnostic sensitivity of the assay.
Discussion
Usually the diagnosis of whooping cough can be done
definitively with the help of polymerase chain reac-
tion. But in some cases a bad correlation between
laboratory results and the clinical picture leads to a
decrease of diagnostic specificity and sensitivity. Diag-
nostic specificity can be optimized by amplification of
a proven germ specific DNA area (4—11), and by
following hygienic precautions, like isolating the work
areas and using filter tips for pipetting (11). In contrast
to serology and culture, high sensitivity of PCR allows
the detection of B. pertussis in early stages of disease
10
ε
s
0.1
100
10
0.1
0.01
ο
ο Cut off
00
·· ·
cP
Cut off
Serologically
negative
Serologically
positive
Fig. 3 Competitive polymerase chain reaction with purified DNA
from nasopharyngeal swabs
Bordetella pertussis DNA was isolated from nasopharyngeal swabs
using phenol/chloroform extraction (see Materials and Methods).
Two groups of patients were tested in this comparison. Serologi-
cally negative children without typical clinical presentations but
proven contact to B. pertussis and serologically positive children
with typical signs of whooping cough. Resulting DNA fragments
were detected after hybridisation with pertussis and internal control
capture probe using Enzymun Test® DNA Detection. Absorbances
at 422 nm for pertussis capture probe are shown in (a). The listed
values in (b) are the ratios A422nm (B. pertussis)/AA22 nm (internal
control DNA).
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and in case of infections of vaccinized patients (3, 11,
18, 19).
Competitive PCR is a useful tool in the identification of
a diminished diagnostic sensitivity. Loss of sensitivity
in PCR assays is mostly due to inhibitory effects (20);
e. g. we found an influence on the amplification of the
target DNA due to insufficient inactivated proteinase K
(see tab. 3), sometimes to haemoglobin and incomplete
removal of phenol. During a competitive PCR an in-
ternal control DNA is coamplified. A diminished ampli-
fication of the internal control DNA discloses such
disturbances in case of a negative detection of the target
DNA. From our point of view one can omit a separate
positive control like a cloned DNA fragment for quality
control because it does not give any evidence of inhibi-
tors in the individual sample and it presents a potential
source of contamination.
Depending on the concentration of the internal control
DNA, its coamplification leads to a reduction of the am-
plification rate of the target DNA (see fig. 1). The sensi-
tivity of the assay therefore has to be calibrated accord-
ing to these demands (see fig. 4), so that the clinically
10
Q
<
1
0.1
100
10
l
0.1
0.01
a o
d ο— ·° .^—
'
Cutoff
b
Cutoff
'
10ΙΟ' ΙΟ'  ΙΟ'12
CQ
Internal control DNA [g]
Fig. 4 Competition of different concentrations of B. pertussis
DNA isolated from nasopharyngeal swabs
Pooled samples from serologically positive children with whooping
cough (a, d), from serologically negative children with contact to
B. pertussis and high absorbances after pertussis capture probe hy-
bridisation (b, e) and samples with low absorbances after hybridisa-
tion with pertussis capture probe (c, f) were tested in competitive
PCR assays with increasing amounts of internal control DNA
(10- l 2- lO'Vassay).
Absorbances at 422 nm after hybridisation with pertussis capture
probe were plotted against internal control DNA quantities per as-
say (a).
Ratios A422nm (B. pertussis DNA)/A422nm (internal control DNA)
were plotted against internal control DNA quantities per assay (b).
relevant germ DNA concentration does not lie beneath
the cut off value.
Today a quantitative interpretation of PCR results is
partly possible in the diagnostics of virus diseases from
homogeneous matrices like blood (13). For detection of
B. pertussis nasopharyngeal swabs are suitable, but in
this case they can be used only with limitations. B. per-
tussis is an obligate pathogen, therefore each positive
result, e. g. after cultivation of the infectious agent, is of
clinical relevance. Quantitative results, however, lead to
a different assessment of the clinical situation. Using
the competitive PCR we could show that a significant
differentiation is possible between patients with typical
clinical symptoms and patients in prodromal stage. For
example it can be of interest to estimate the infectious-
ness during incubation stage. This is possible with the
help of the target DNA/control DNA ratio.
A known disadvantage of a PCR assay is the detection
of dead bacterial cells. Regarding the estimation of in-
fectiousness the microbiological culture shows a better
diagnostic specificity. Here positive results correlate
well with the clinical condition. Therefore the PCR has
priority in early diagnostics. With existing older infec-
tions a possibly still existing infectiousness can riot be
estimated because the bacteria die during the catarrhal
stage. We obtained very weak positive results in some
PCR positive patients who had proven contact with B.
pertusis infected persons (see fig. 4). A semiquantitative
estimation with the help of the competitive PCR points
to a number of bacterial cells that is clearly below nor-
mally measured values (see fig. 4). After a few days a
control test should give further information about the
infectiousness under consideration of the target DNA/
control DNA ratio.
We find the competitive PCR to be a fast and depend-
able procedure for the diagnosis of whooping cough.
Analytical sensitivity of single assays could be better
controlled. The specificity of a result can be interpreted
under consideration of the clinical condition and includ-
ing the relation of target DNA to internal control DNA
amplification. The clinical impact of the competitive
PCR with weak positive results must be tested with a
much bigger number of samples in correlation with the
clinical findings.
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